Peanut OIT involves eating small, gradually increasing amounts of peanut protein daily.
Currently, the NIAID - supported Immune Tolerance Network is conducting a randomized trial called IMPACT to determine whether
peanut OIT can lower the risk of allergic reactions, induce tolerance and change the immune responses of peanut - allergic children aged 12 to 48 months.
They randomly assigned participants to either high - dose
peanut OIT with a target daily dose of 3,000 milligrams peanut protein or a low - dose regimen with a target dose of 300 milligrams.
Previous studies with older children showed that
peanut OIT can offer some protection against potentially life - threatening anaphylaxis caused by peanut exposure.
Not exact matches
Comparison of the
OIT - treated children with a control group of 154
peanut - allergic children who had avoided
peanut showed that
OIT - treated children were 19 times more likely to successfully incorporate
peanut into their diets.
Low - dose and high - dose
OIT were safe and equally effective at suppressing allergic immune responses to
peanut, investigators found.
After receiving
OIT for 29 months on average, participants avoided
peanut completely for four weeks before attempting to reintroduce it into their diets.
Nearly 80 percent of
peanut - allergic preschool children successfully incorporated
peanut - containing foods into their diets after receiving
peanut oral immunotherapy (
OIT), a clinical trial has found.